La Merie Publishing
La Merie Business Intelligence is focused on Research and Development in the Biopharmaceutical Industry. La Merie provides information about biopharmaceutical R&D and competitive intelligence. The information is retrieved from La Merie’s in house R&D database, news portal and direct, as well as desktop searches. La Merie has a focus on Biologics, including antibodies, proteins, peptides, vaccines, RNA, DNA and cell therapy.
La Merie publishes Competitor Analysis Reports, Brief Reports and Full Reports. The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced. Brief Reports on Target Pipelines include assessment of the scientific, as well as business perspective of new targets. Full reports provide in-depth analysis of product portfolios, R&D pipelines, competitive environment and a critical assessment of the pipeline perspective.
The Competitive Intelligence Report Anthrax Vaccines & Therapeutics as of June 2013 provides a competitor analysis in the development pipelines of novel vaccines and therapeutics for prophylaxis of Bacillus anthracis infection and treatment of anthrax. Purchase of the pdf report includes a 6-month online ...
Jun, 2013 32 pagesThe Competitive Intelligence Report Coagulation Factors provides a competitor analysis of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of May 2013. Purchase of the pdf report includes a 6-month online access ...
May, 2013 158 pagesThe Competitive Intelligence Report Thrombolytics & Fibrinolytics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel thrombolytics and fibrinolytics for treatment of cardiovascular thrombosis, stroke and eye diseases. Purchase of the pdf report includes ...
May, 2013 38 pagesThe Competitive Intelligence Report Human Papilloma Virus (HPV) Vaccines & Therapeutics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel vaccines and therapeutics for prophylaxis of HPV infection and HPV-induced neoplasias and treatment of HPV-induced ...
May, 2013 43 pagesThe new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated ...
May, 2013 301 pagesProduct description The Competitive Intelligence Report Insulin as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant insulin and insulin analogs for the treatment of type 1 and type 2 diabetes mellitus. Purchase of the pdf report includes ...
Apr, 2013 89 pagesProduct description The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the ...
Apr, 2013 104 pages... agents for treatment of thrombocytopenia. In addition, the report lists company-specific product portfolios and R&D pipelines of Thrombopoiesis Stimulating Agents (TPO; IL-11). Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of ...
Apr, 2013 15 pagesProduct description The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural interferon alpha, beta, gamma, lambda and of other subtypes for treatment of hepatitis B and C, other ...
Apr, 2013 89 pagesProduct description The Competitive Intelligence Report Human Growth Hormone (hGH) as of April 2013 provides a competitor analysis in the development pipeline of biosimilar versions of somatropin and next generation biobetter/biosuperior hGH products for treatment of growth hormone deficiency (GHD) in ...
Apr, 2013 49 pages... and development. In addition, the report lists company-specific product portfolios and R&D pipelines of Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) on the market or in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of ...
Apr, 2013 94 pages... , Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, ...
Apr, 2013 72 pages... legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to ... the different in vitro and in antibody generation technologies. Attrition rate was defined as the percentage of failed antibodies of all active and inactive ...
Mar, 2013 607 pages... (ART) as of February 2013 provides a competitor analysis in the development pipeline of novel recombinant and purified FSH, hCG and LH receptor agonists for ... , the report lists company-specific R&D pipelines of FSH, LH and hCG products and projects. Competitor projects are listed in a tabular format providing ...
Feb, 2013 43 pages... Intelligence Report Enzyme Replacement & Enhancement Therapies (ERT) as of January 2013 provides a competitor analysis in the development pipeline of novel enzyme replacement therapies and of enzyme enhancement therapies to treat human genetic diseases/lysosomal storage diseases and exocrine pancreatic ...
Jan, 2013 74 pages... description The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists & Antagonists provides a competitor analysis in the development pipeline of novel small ... with the project data to print or export an individual report. Toll-like receptors (TLRs) are a class of proteins that play a key role ...
Dec, 2012 178 pages... infect humans. HSV-1 and HSV-2 cause the viral disease herpes simplex which can be categorized into one of several distinct disorders ... . In addition, the report lists company-specific R&D pipelines of Herpes Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information ...
Dec, 2012 56 pagesThe present Competitive Intelligence Report about EGF-R Antibodies –Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of December 2012. Purchase of the downloadable pdf report ...
Dec, 2012 38 pages... Synagis Prolia/Xgeva Soliris Stelara Zenapax More than 140 biosimilar antibodies are in the pipeline with the first molecules approved ... with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information ...
Dec, 2012 142 pages... next couple of years and are paving the way for biosimilar antibodies. The first Avastin biosimilars are already in clinical trials and ... diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...
Nov, 2012 64 pagesThe present Competitive Intelligence Report about TNF Antibodies –Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of November 2012. ...
Nov, 2012 82 pages... (2011 sales of over US$ 5.5 bln). Herceptin is approved and marketed for Her2 positive breast and gastric cancer. Genentech and Roche are ... cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...
Nov, 2012 44 pages
